Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

DIBROMPROPAMIDINE DIISETIONATE CRS (10 MG)

DIBROMPROPAMIDINE DIISETIONATE CRS (10 MG)

614-87-9

DISCOVER
DIBROMPROPAMIDINE FOR SYSTEM SUITABILITY CRS (20 MG)

DIBROMPROPAMIDINE FOR SYSTEM SUITABILITY CRS (20 MG)

614-87-9

DISCOVER
DIHYDROTACHYSTEROL FOR SYSTEMSUITABILITY CRS (5 MG)

DIHYDROTACHYSTEROL FOR SYSTEMSUITABILITY CRS (5 MG)

67-96-9

DISCOVER
HYOSCINE CRS (15 MG)

HYOSCINE CRS (15 MG)

51-34-3

DISCOVER
HYOSCINE IMPURITY A CRS (15 MG)

HYOSCINE IMPURITY A CRS (15 MG)

NA

DISCOVER
MYO-INOSITOL CRS (2020 MG)

MYO-INOSITOL CRS (2020 MG)

87-89-8

DISCOVER
KETOROLAC TROMETAMOL CRS (15 MG)

KETOROLAC TROMETAMOL CRS (15 MG)

74103-07-4

DISCOVER
LEFLUNOMIDE IMPURITY A CRS (30 MG)

LEFLUNOMIDE IMPURITY A CRS (30 MG)

455-14-1

DISCOVER
HUMAN IMMUNOGLOBULIN (MOLECULAR SIZE) BRP (10 ML)

HUMAN IMMUNOGLOBULIN (MOLECULAR SIZE) BRP (10 ML)

9007-83-4

DISCOVER
MYCOPHENOLATE MOFETIL CRS (30MG)

MYCOPHENOLATE MOFETIL CRS (30MG)

128794-94-5

DISCOVER
MISOPROSTOL CRS (100 MG)

MISOPROSTOL CRS (100 MG)

59122-46-2

DISCOVER
OXYCODONE HYDROCHLORIDE CRS -* NARC (70 MG)

OXYCODONE HYDROCHLORIDE CRS -* NARC (70 MG)

124-90-3

DISCOVER